- Home
- PNRG vs ESPR Comparison
PNRG vs ESPR Comparison
Compare PNRG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNRG
- ESPR
- Stock Information
- Founded
- PNRG 1973
- ESPR 2008
- Country
- PNRG United States
- ESPR United States
- Employees
- PNRG N/A
- ESPR N/A
- Industry
- PNRG Oil & Gas Production
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- PNRG Energy
- ESPR Health Care
- Exchange
- PNRG Nasdaq
- ESPR Nasdaq
- Market Cap
- PNRG 340.1M
- ESPR 399.0M
- IPO Year
- PNRG N/A
- ESPR 2013
- Fundamental
- Price
- PNRG $174.17
- ESPR $2.25
- Analyst Decision
- PNRG
- ESPR Buy
- Analyst Count
- PNRG 0
- ESPR 5
- Target Price
- PNRG N/A
- ESPR $7.30
- AVG Volume (30 Days)
- PNRG 6.8K
- ESPR 8.8M
- Earning Date
- PNRG 11-14-2024
- ESPR 11-07-2024
- Dividend Yield
- PNRG N/A
- ESPR N/A
- EPS Growth
- PNRG 71.12
- ESPR N/A
- EPS
- PNRG 23.14
- ESPR N/A
- Revenue
- PNRG $210,064,000.00
- ESPR $295,451,000.00
- Revenue This Year
- PNRG N/A
- ESPR $186.90
- Revenue Next Year
- PNRG N/A
- ESPR $31.10
- P/E Ratio
- PNRG $8.00
- ESPR N/A
- Revenue Growth
- PNRG 88.03
- ESPR 187.12
- 52 Week Low
- PNRG $92.40
- ESPR $1.58
- 52 Week High
- PNRG $220.50
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- PNRG 40.56
- ESPR 44.07
- Support Level
- PNRG $183.50
- ESPR $1.84
- Resistance Level
- PNRG $220.50
- ESPR $2.54
- Average True Range (ATR)
- PNRG 9.68
- ESPR 0.43
- MACD
- PNRG -3.67
- ESPR -0.12
- Stochastic Oscillator
- PNRG 0.09
- ESPR 23.57
About PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and provide well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.